All In Biotech

Free tool

FAERS Monitor: Cosopt Pf

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202667 or its brand name (Cosopt Pf, Dorzolamide Hydrochloride, Timolol Maleate). Reports on generic versions are filed under their own applications.

Reports

2,587

Serious

782

30% of reports

Hospitalization

123

Death reported

320

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye irritation513
  • ocular hyperaemia453
  • eye pruritus308
  • drug ineffective256
  • eye pain227
  • death210
  • eye swelling195
  • vision blurred139
  • lacrimation increased130
  • hypersensitivity128
  • dyspnoea101
  • glaucoma97
  • treatment failure95
  • bronchitis81
  • drug intolerance80

Reports by year received

View as table
YearReports
20042
20061
20082
200912
201030
201128
201217
2013101
201427
20157
201686
2017181
2018187
2019463
2020601
2021283
2022196
2023171
202462
202570
202660

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,572 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ocular hyperaemiaSignal45378.372.034,260
eye pruritusSignal30875.267.722,307
eye irritationSignal51373.167.636,187
eye swellingSignal19542.837.47,898
glaucomaSignal9741.233.83,746
lacrimation increasedSignal13035.129.74,264
eye painSignal22732.829.06,966
treatment failureSignal959.37.7700
bronchitisSignal818.97.2562
vision blurredSignal1398.27.0882
drug intoleranceSignal806.75.4387
hypersensitivitySignal1285.64.7484
death2102.01.7105
drug ineffective2561.61.457
dyspnoea1011.51.214

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.